Stocks and Investing Stocks and Investing
Tue, March 26, 2019
Mon, March 25, 2019
Fri, March 22, 2019

Christopher Marai Maintained (BIIB) at Strong Buy with Decreased Target to $320 on, Mar 22nd, 2019


Published on 2024-10-26 12:43:42 - WOPRAI, Christopher Marai
  Print publication without navigation


Christopher Marai of Nomura, Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $420 to $320 on, Mar 22nd, 2019.

Christopher has made no other calls on BIIB in the last 4 months.



There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, all agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Alethia Young of "Cantor Fitzgerald" Downgraded from Buy to Hold on, Thursday, March 21st, 2019
  • Matt Phipps of "William Blair" Downgraded from Buy to Hold on, Thursday, March 21st, 2019
  • Steve Chesney of "Atlantic Equities" Downgraded from Buy to Hold on, Thursday, March 21st, 2019
  • Ian Somaiya of "BMO Capital" Initiated at Hold and Held Target at $322 on, Friday, February 22nd, 2019
  • Adnan Butt of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $325 on, Friday, February 22nd, 2019
  • Thomas Shrader of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $346 on, Thursday, February 21st, 2019

Contributing Sources